Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 50.7%

Neg 50.7% Neu 0% Pos 0%

Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $43 to $35.